Molecule identified as key in pancreatic cancer metastasis
New findings show that the environment for pancreatic cancers plays a role in its metastasis, revealing a new potential drug target.
A team of researchers have revealed that aggressive pancreatic cancer cells use a molecule to change their environment, enabling metastasis. According to the researchers, the surroundings of tumours is a potential untapped resource for cancer therapy and one they intend to explore further.
…the team observed that non-metastatic cancers began to spread when combined with metastatic fibroblasts
The investigation, conducted by the Garvan Institute of Medical Research, Australia, compared metastatic and non-metastatic pancreatic cancers. The tissue is known as the ‘matrix’, similar to a glue that holds different cells in an organ or tumour together.
Using a mouse model, the researchers extracted fibroblasts from both types of tumours. Mixing these with the opposite cancer cells, the team observed that non-metastatic cancers began to spread when combined with metastatic fibroblasts.
“Our results suggest that some pancreatic cancer cells can ‘educate’ the fibroblasts in and around the tumour. This lets the fibroblasts remodel the matrix and interact with other, less aggressive cancer cells in a way that supports the cancer cells’ ability to spread,” said first author Dr Claire Vennin.
The researchers used mass spectrometry techniques to further investigate the fibroblasts. They discovered several molecules from metastatic tumours that were produced at higher rates than in the non-metastatic tumours.
The team found that the metastatic pancreatic tumours produce more of a molecule called perlecan. Using gene editing techniques, the researchers reduced the levels of perlecan in mouse models of aggressive metastatic pancreatic cancer. Through advanced live imaging techniques, they tracked individual cancer cells and revealed that lowered perlecan decreased the spread of tumours which also then responded better to chemotherapy.
“If we can specifically target the aggressive fibroblasts in patients harbouring precise genetic changes, we can make them more susceptible to our currently approved treatments, which would significantly change how we treat this aggressive cancer,” said Dr Vennin.
“Most cancer therapies today aim to target cancer cells themselves. The environment of tumours is a potential untapped resource for cancer therapy and one which we intend to explore further,” said Associate Professor Paul Timpson, Head of the Invasion and Metastasis Laboratory at the Garvan Institute.
The findings were published in Nature Communications.